Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 373 | 93 | 269 |
| Samples | 230 | 72 | 151 |
| Peptides | 174 | 52 | 125 |
Function
ADRA2C · Adrenoceptor alpha 2C
Alpha-2-adrenergic receptors are members of the G protein-coupled receptor superfamily. They include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. These receptors have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. The mouse studies revealed that both the alpha2A and alpha2C subtypes were required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons. The alpha2A subtype inhibited transmitter release at high stimulation frequencies, whereas the alpha2C subtype modulated neurotransmission at lower levels of nerve activity. This gene encodes the alpha2C subtype, which contains no introns in either its coding or untranslated sequences. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 169 amino-acid changes on canonical ENST00000330055 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ADRA2C · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ADRA2C – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Acute Monocytic Leukemia | 0/1 0% | 2/25 8% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 8/612 1% |
| Colorectal Carcinoma | 20/143 14% | 36/3239 1% |
| Neuroendocrine Tumour | 9/154 6% | 1/577 0% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Gastric Carcinoma | 1/74 1% | 14/1809 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Glioma | 3/52 6% | 12/2127 1% |
| Other Sarcomas | 3/69 4% | 2/699 0% |
| Melanoma | 5/210 2% | 8/1899 0% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 5/1390 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Other Solid Cancers | 0/94 0% | 7/1515 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Hepatocellular Carcinoma | 0/46 0% | 7/2210 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Head and Neck Carcinoma | 1/85 1% | 4/1574 0% |
| Pancreatic Carcinoma | 2/89 2% | 3/1611 0% |
| Ovarian Carcinoma | 1/109 1% | 2/998 0% |
| Kidney Carcinoma | 1/85 1% | 3/1862 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Other Blood Cancers | 3/61 5% | 2/2725 0% |
Mutation Distribution
Where ADRA2C is mutated · all tissues, split by cell line vs tissue
How many mutations in ADRA2C were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 373 mutations in ADRA2C
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|